Replies to post #22647 on GOOD TRADERS FORUM

[powerbattles]

Thank you my friend!

[powerbattles]

(QNTA) Quanta, Inc. .09 Basic Due Diligence Package



Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who has completed all research and the development process and has attained the legal registration to commercialize the Blue Scorpion venom based product under the name of Escozine.

https://medolife.com/

Escozine™ was originally developed and commercialized by Medolife, Corp. in 2007. Until 2007, this natural medicine has only been available in Cuba, where it is known as Escozul. Medolife currently holds the exclusive patent license, (United States patent # 8,097,284 B2) of the bioactive peptide and polarization technology used to make the Polarized Dilute Blue Scorpion Venom. Escozine™, is registered and certified for oncological treatment by the Minister of Health in the Dominican Republic. Escozine™ is currently distributed in six countries (Dominican Republic, Vietnam, Russia, Belarus, Nigeria and Kazakhstan).

Escozine has been used for years to treat humans with cancer in many countries and its positive results are backed by numerous scientific research, pre-clinical and clinical observations that confirm its safety and efficacy.

Medolife has been successfully marketing its Escozine products through direct sales in 40 countries. Medolife has invested over $10 million in R&D in Escozine (for humans) over 10 years and amassed substantial scientific documentation, worldwide of its effectiveness.

CLOSER TO FDA APPROVAL, for its Pre-Investigational New Drug (PIND #150335) filing on its lead drug candidate Escozine® as a COVID-19 therapeutic. May 13th marks 30 days since the application.

Escozine® is a patented anti-cancer nutraceutical derived from the Caribbean blue scorpion that shows an 89.5% success rate in clinical trials

ESCOZINE-HPOur latest product combines the power of Escozine with renown homeopathic ingredients Bryonia albaand Echinacea purpurea for cancer patients undergoing or recovering from chemotherapy. National Drug Code 70891-201-01

AMAZING VIDEO: MEDOLIFE PRESENTS THE PRODUCE OF ESCOZINE

Medolife has its own independent source of Blue Scorpion venom in the Dominican Republic and has established the world’s first Scorpion reservation which is 50,000 square meters and can produce millions of doses to meet global demand.

Escozine™ serum has demonstrated promising results in human preclinical studies in 2012 at UCSD Moores Cancer Center, as well as human clinical observations; results from UCSD also showed that Escozine had significant synergy with traditional chemotherapy agents cyclophosphamide, Fludarabine, Etoposide and others. Many Escozine users have combined the product with chemotherapy, radiation, hormone therapy and other conventional treatments with positive results. In 2007, Medolife collaborated with Atheris Laboratory in Switzerland, one of the world leaders in the study and analysis of crude venoms, to confirm that the venom of Rhopalurus Junceus from Cuba and Rhopalurus Princeps from Dominican Republic both share similar properties and have similar mechanisms of action in cancer cells.

In 2012, UCSD (University of California San Diego, Moores Cancer Center, together with Medolife Corp.) conducted research using polarized dilute Blue Scorpion venom utilizing the Mikaelian patented process # US 8097284 B2. The results demonstrated up to 95% apoptotic (programmed cell death) effect in a variety of cancer cell lines incubated for 48 hours, and showed a binding preference to cancer cells only while not affecting normal cells. Additionally, the study showed a synergistic effect with traditional chemotherapy treatments. Research anticipates that PetLife’s Escozine for Pets™ will also extend the life of pets suffering from cancer and improve their quality of life.

ABC NEWS! Old but well worth to view.

Medolife said Escozine is an effective cancer treatment because a peptide in the venom called chlorotoxin -- the same chemical that paralyzes prey -- also happens to target and kill cancer cells.
https://abcnews.go.com/Health/scorpion-venom-cure-ails/story?id=20755012

Very Interesting:))How Scorpion Venom Is Helping Doctors Treat Cancer. When injected into the body, Tumor Paint lights up cancers. The drug could lead to a new class of therapeutics

https://www.smithsonianmag.com/innovation/how-scorpion-venom-is-helping-doctors-treat-cancer-180960815/

Amazing! Targeting brain cancer with scorpion venom

Quanta Inc (OTCMKTS:QNTA) Groundbreaking Results In Escozine® Testing
https://drpgazette.com/2021/04/09/quanta-inc-otcmktsqnta-groundbreaking-results-in-escozine-testing/

I read this news again and thinking this is much bigger than I thought...

The registration was renewed after the Company provided study data on the efficacy of Escozine® in assisting cancer treatments of various kinds including common types of cancer such as breast, prostate, lung, and some uncommon forms of cancer such as bladder and ovarian. The registration allows for Escozine® to be marketed as a bioactive alternative cancer medicine across the DR and most other countries in Latin America, where the burden of cancer and mortality rates are among the highest in the world.

The Company also plans to negotiate with the government in the DR for the purchase of Escozine® for use as a treatment for COVID-19.

https://www.globenewswire.com/news-release/2021/05/04/2222245/0/en/Medolife-Rx-Announces-Historic-Product-Registration-in-Dominican-Republic-Enabling-Escozine-to-Be-Sold-Throughout-Latin-America-as-Natural-Alternative-Cancer-Medicine.html

Medolife Rx Receives Significant Purchase Order of Immunapen. The purchase order for 1,400 Immunapen™ Originals came from a pharmaceutical wholesaler based in the Republic of Armenia who will distribute the products throughout the region. This is the first purchase order from the wholesaler and the Company hopes that it will be the beginning of a strong relationship.

The Company also has developed Immunapen™ Anti-Anxiety, Immunapen™ Sleep, and Immunapen™ Energy & Focus.

https://ir.quantrx.com/news-events/press-releases/detail/57/medolife-rx-receives-significant-purchase-order-of

Quanta PRODUCTS are being Sold on Amazon
https://www.amazon.com/s?k=quanta+cream&crid=2PIYH1N70PCN2&sprefix=quanta+%2Caps%2C197&ref=nb_sb_ss_ts-doa-p_9_7

QUANTA PRODUCTS:
https://quantrx.com/shop/

QUANTA VIDEO:
https://quantrx.com/quanta-videos/

Management Team:

Arthur G. Mikaelian.


For the past 20 years Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of nutraceuticals and pharmaceutical drugs, as well as expanding his interests in cancer and oncology.

One of Dr. Mikaelian’s greatest scientific contributions and ground-breaking inventions is his Polarization technology which targets key elements in the main ingredients of medications, leading to the intensification of potency of liquid or solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it.

Dr. Mikaelian’s technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky University. He also earned an MBA from the University of Bologna, located in Italy.



Prof. Khalid Z Matalka

Dean of Faculty of Health Sciences
Professor of Immunology
American University of Madaba
Jordan
Tel: [phone]

Full_biography:
https://scholars.direct/editor-Full_biography.php?jid=immunology&eid=LB93695207

For the past 20 years Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of nutraceuticals and pharmaceutical drugs, as well as expanding his interests in cancer and oncology.

One of Dr. Mikaelian’s greatest scientific contributions and ground-breaking inventions is his Polarization technology which targets key elements in the main ingredients of medications, leading to the intensification of potency of liquid or solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it.

Dr. Mikaelian’s technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky University. He also earned an MBA from the University of Bologna, located in Italy.

More on Magagement team view link below:
https://ir.quantrx.com/company-information/management-team

Share Structure:

Market Cap Market Cap
9,493,409 05/11/2021
Authorized Shares
500,000,000 04/09/2021
Outstanding Shares 102,079,666 04/09/2021
Restricted 24,436,248 04/09/2021
Unrestricted 77,643,418 04/09/2021